Health · 2 views
‘Who knows what they’re taking?’: people risk the gray market for the newest weight-loss drug
Made by Eli Lily, retatrutide is a triple agonist, targeting the GLP-1 and GIP receptors and glucagon.
Source Story Brief Updated 19h 36m ago
Health 
Story intelligence Beta
Confidence Limited Single-outlet story
Views 2 Community interest
Brief read ~41 words
Story Brief
Made by Eli Lily, retatrutide is a triple agonist, targeting the GLP-1 and GIP receptors and glucagon. Photograph: LPETTET/Getty Images View image in fullscreen Made by Eli Lily, retatrutide is a triple agonist, targeting the GLP-1 and GIP receptors and glucagon.
Read full article on The GuardianAI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Digital strategy helps patients with heart failure to receive proven medicationContinue reading
- After TAVI, anticoagulants outperform antiplatelet agents at preventing clotsContinue reading
- Public confidence in one's own health care provider remains highContinue reading
- High fertility costs push Americans abroad for IVF treatmentContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow